Oxidative DNA damage and total antioxidant status in glaucoma patients.
OBJECTIVE
To evaluate DNA damage markers and the antioxidant status of serum and aqueous humor in glaucoma patients.


METHODS
Aqueous humor and serum samples were obtained at the time of surgery from 28 patients with glaucoma and 27 patients with cataracts. Total antioxidant status (TAS) and 8-hydroxy-2´-deoxyguanosine (8-OHdG) levels of all samples were determined by spectrophotometric and enzyme-linked immunosorbent assay methods.


RESULTS
Aqueous levels of 8-OHdG were higher in glaucoma patients than in the cataract group (4.61±2.97 ng/ml versus 1.98±0.70 ng/ml, p=0.002). Serum levels of 8-OHdG were also higher in glaucoma patients than in the cataract group (17.80±8.06 ng/ml versus 13.63±3.54 ng/ml, p=0.046). The TAS levels of serum (0.55±0.13 mmol/lit versus 0.70±0.14, p=0.001), and aqueous humor (0.23±0.13 mmol/lit versus 0.34±0.15, p=0.001) in glaucoma patients were lower than in cataract patients.


CONCLUSIONS
Our findings provide evidence that oxidative DNA damage increases and TAS decreases in the serum and aqueous humor of glaucoma patients. These findings support the hypothesis that the formation of reactive oxygen species and/or a decrease in TAS may have an important role in the pathogenesis of glaucoma.
Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Rana
R
Sorkhabi
Amir
A
Ghorbanihaghjo
Alireza
A
Javadzadeh
Nadereh
N
Rashtchizadeh
Melorina
M
Moharrery
D000080242:8-Hydroxy-2'-Deoxyguanosine; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000975:Antioxidants / Q000737:chemistry*; D002386:Cataract / Q000378:metabolism; D003430:Cross-Sectional Studies; D004249:DNA Damage; D003849:Deoxyguanosine / Q000031:analogs & derivatives / Q000494:pharmacology; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D005901:Glaucoma / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015233:Models, Statistical; D018384:Oxidative Stress; D013053:Spectrophotometry / Q000379:methods
D000975:Antioxidants; D000080242:8-Hydroxy-2'-Deoxyguanosine; D003849:Deoxyguanosine
Invest Ophthalmol Vis Sci. 1996 Dec;37(13):2744-9
8977490
Invest Ophthalmol Vis Sci. 2005 Mar;46(3):877-83
15728543
J Glaucoma. 2008 Jun-Jul;17(4):263-8
18552610
Br J Pharmacol. 2004 May;142(2):231-55
15155533
Mutat Res. 2006 Mar;612(2):105-14
16413223
Invest Ophthalmol Vis Sci. 2007 Oct;48(10):4580-9
17898281
Exp Eye Res. 2007 Mar;84(3):389-99
17196589
Am J Ophthalmol. 2004 Jan;137(1):62-9
14700645
Vision Res. 1998 Oct;38(19):2881-8
9797984
Ophthalmologica. 1981;182(3):141-7
7267002
Ophthalmol Clin North Am. 2002 Mar;15(1):61-8
12064082
Surv Ophthalmol. 1999 Jun;43 Suppl 1:S129-35
10416755
Mol Aspects Med. 2002 Feb-Jun;23(1-3):101-208
12079771
J Glaucoma. 2009 Dec;18(9):662-5
20010244
Br J Nutr. 2004 Jun;91(6):809-29
15182385
Nat Med. 2001 Mar;7(3):294-5
11231625
Ophthalmologica. 2001 Jan-Feb;215(1):34-8
11125267
Clin Chem. 2006 Apr;52(4):601-23
16484333
Invest Ophthalmol Vis Sci. 1997 Mar;38(3):690-6
9071223
Biochem Med. 1984 Apr;31(2):217-27
6721870
Cancer Res. 1996 Apr 1;56(7):1642-7
8603414
Free Radic Biol Med. 2002 May 15;32(10):968-74
12008112
Clin Exp Optom. 2002 Nov;85(6):335-49
12452784
Am J Med. 2003 Jun 1;114(8):638-46
12798451
Clin Exp Pharmacol Physiol. 2000 Jan-Feb;27(1-2):100-6
10696536
Am J Ophthalmol. 1992 Apr 15;113(4):447-52
1558122
Am J Ophthalmol. 2000 Nov;130(5):589-96
11078837
Arch Ophthalmol. 2005 Apr;123(4):458-63
15824217
Nutrition. 2002 Mar;18(3):291-2
11882411
Nat Med. 2001 Mar;7(3):304-9
11231628
Invest Ophthalmol Vis Sci. 1998 May;39(6):1053-8
9579487
Ophthalmologica. 2000 Jan-Feb;214(1):78-85
10657746
Exp Eye Res. 1981 Dec;33(6):673-81
7318962
Arch Soc Esp Oftalmol. 2000 Mar;75(3):141-2
11151137
Lancet. 2004 May 22;363(9422):1711-20
15158634
Free Radic Biol Med. 2002 Jun 1;32(11):1102-15
12031895
Eye (Lond). 2008 Mar;22(3):445-53
17293786
J Cell Physiol. 2007 Jan;210(1):99-110
16998801
Ophthalmologe. 2004 Apr;101(4):357-65
15067416
Bioessays. 1997 Feb;19(2):161-6
9046246
Eye (Lond). 2005 May;19(5):580-3
15332106